GlassScriptPhysician profile
Lisa V Blair
NPI 1699149856
$4,162.13
in general payments reported to CMS, 2019-2025
34 companies · $19.04 in 2025
The $19.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $1,953 · 2023: $1,740 · 2024: $343 · 2025: $19.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,064.30 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $552.30 | 2021-2025 | |
| Glaxosmithkline, LLC. | $256.99 | 2022-2024 | Trelegy Ellipta |
| Pfizer INC. | $252.35 | 2023-2024 | |
| Lilly USA, LLC | $208.30 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $187.92 | 2022-2024 | Farxiga, Airsupra |
| Abbott Laboratories | $159.45 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.10 | 2022-2024 | Ofev, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $117.74 | 2022 | |
| Amgen INC. | $113.81 | 2022-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $111.86 | 2022-2024 | Rexulti |
| Antares Pharma, INC. | $94.68 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Astellas Pharma US INC | $93.95 | 2022-2023 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.86 | 2022-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $72.46 | 2022-2023 | Belsomra, Verquvo, Steglatro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $70.75 | 2021-2022 | |
| Exact Sciences Corporation | $70.74 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $62.14 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $60.55 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $58.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.19 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $42.19 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.91 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $26.70 | 2023 | |
| Nevro Corp. | $25.23 | 2023 | Senza |
| Dexcom, INC. | $24.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.34 | 2023 | Seglentis |
| Mylan Specialty L.P. | $15.75 | 2023 | Yupelri |
| Horizon Therapeutics Plc | $15.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.54 | 2023 | Linzess |
| Halozyme INC | $13.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.